RA Capital Management Increases SpyGlass Pharma Stake by $172M, Including $59M Open Market Buy

summarizeSummary

RA Capital Management, a significant institutional investor and director, substantially increased its stake in SpyGlass Pharma through a $59 million open market purchase and $113 million in preferred stock conversions, totaling over $172 million in common stock acquired.

check_boxKey Events

• Substantial Common Stock Acquisition

  RA Capital Management, a Director and 10% Owner, acquired $172.4 million worth of SpyGlass Pharma common stock.

• Significant Open Market Purchase

  This includes a $59.04 million open market purchase of 3,690,000 shares at $16.00 per share.

• Preferred Stock Conversion

  An additional $113.39 million in common stock was acquired through the conversion of preferred stock.

• Major Stake Increase

  The total acquisition represents a very significant increase in the institutional investor's stake, demonstrating strong conviction.

auto_awesomeAnalysis

This Form 4 filing reveals a highly significant accumulation of SpyGlass Pharma common stock by RA Capital Management, L.P., a major institutional investor with board representation. The transactions include a substantial $59 million open market purchase at $16.00 per share, alongside the conversion of over $113 million in preferred stock into common stock. This combined acquisition of over $172 million in common stock represents a very large commitment to the company's equity. The timing of these transactions, occurring on February 9, 2026, just days before the filing date, and the cluster of similar large insider purchases by other 10% owners on the same day, signals strong conviction from key institutional holders. The open market purchase price of $16.00 is notably below the current stock price of $26.18, indicating a significant paper gain for RA Capital on this specific transaction. This aggressive accumulation by a sophisticated investor group suggests high confidence in the company's future prospects.